Clinical Innovations Acquires babyLance™ Safety Heelstick from MediPurpose
Expands Market Reach for Innovative Neonatal Heelstick Device
Known for its ease of use, smooth incisions and consistent blood volumes, babyLance safety heelsticks are sterile, single-use neonatal heel incision devices that are used to produce blood samples for testing. Available in four configurations, babyLance models are primarily differentiated by their incision depths, which are optimized for micropreemies (0.60 mm), preemies (0.85 mm), newborns (1.0 mm) and toddlers (1.4 mm).
Clinical Innovations, the largest medical device company exclusively focused on labor and delivery, acquired the innovative neonatal medical device to support its NICU expansion strategy.
Introduced in 2010 and redesigned in 2011, babyLance is MediPurpose’s second independently developed and commercialized medical device—and its first to be acquired by another company.
MediPurpose founder and CEO Patrick Yi, who led babyLance’s design and development, is eager to see Clinical Innovations expand his medical device’s market reach. “We are very proud of the success our sales and marketing team has accomplished with introducing babyLance to the neonatal medical device market,” said Yi. “Clinical Innovations has the resources and experience to accelerate the acceptance of babyLance by neonatal nurses.”
Validating the Design and Development of the ‘Ideal Heelstick’
babyLance was closely designed with neonatal nurses to meet their expectations for “the ideal heelstick solution,” said Yi.
Yi said the device delivers one of the industry’s smoothest incisions, which reduces trauma to an infant’s delicate subcutaneous tissues. “Neonatal nurses will regularly perform several heelsticks a day on an infant throughout its stay in NICU,” said Yi. “It’s crucial that each incision is as smooth as possible in order to yield an adequate volume of blood and to prevent repeating the procedure.”
“We left no stone unturned with babyLance,” said Yi. “In the NICU, the smallest details matter to neonatal nurses. All features were designed and tested to ensure that they helped neonatal nurses perform their jobs more safely and easily.”
“The acquisition validates the value of MediPurpose’s rigorous design and development processes,” said Yi. “Whether it was the SurgiLance™ safety lancet that launched the company in 1999, babyLance, or new medical devices that we are currently developing, the objective is always to do whatever it takes to listen to end users and give them what they want.”
Founded in 1999, MediPurpose is a boutique medical product company with offices and partnerships in the United States, Canada, EMEA/LA and Asia.
MediPurpose’s Medical Device Innovation and Medical Product Distribution divisions provide product research and development consultation for new medical device inventors and innovative medical product companies that seek entrance into new medical product markets—which includes angel funding, feasibility studies and commercialization, among other services.
For more information about MediPurpose, please visit medipurpose.com.
About Clinical Innovations
Clinical Innovations is the largest medical device company exclusively focused on labor and delivery. Already a market leader in several categories with products such as the Koala® Intrauterine Pressure Catheter; Kiwi® Vacuum-Assisted Delivery System; ROM Plus® Rupture of Membranes Test; traxi® Panniculus Retractor and ClearView Uterine Manipulator. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. Clinical Innovations is a Pritzker Group company.
For more information about Clinical Innovations, please visit clinicalinnovations.com.